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Recombinant follicle-stimulating hormone (FSH) (follitropin alfa) and biosimilar
preparations are available for clinical use. They have specific FSH activity and a unique
glycosylation profile dependent on source cells. The aim of the study is to compare the
originator (reference) follitropin alfa (Gonal-f®)- with biosimilar preparations (Bemfola®
and Ovaleap®)-induced cellular responses in vitro. Gonadotropin N-glycosylation profiles
were analyzed by ELISA lectin assay, revealing preparation specific-patterns of glycan
species (Kruskal-Wallis test; p < 0.05, n = 6) and by glycotope mapping. Increasing
concentrations of Gonal-f® or biosimilar (1× 10−3-1× 103 ng/ml) were used for treating
human primary granulosa lutein cells (hGLC) and FSH receptor (FSHR)-transfected
HEK293 cells in vitro. Intracellular cAMP production, Ca2+ increase and β-arrestin
2 recruitment were evaluated by BRET, CREB, and ERK1/2 phosphorylation by
Western blotting. 12-h gene expression, and 8- and 24-h progesterone and estradiol
synthesis were measured by real-time PCR and immunoassay, respectively. We
found preparation-specific glycosylation patterns by lectin assay (Kruskal-Wallis test;
p < 0.001; n = 6), and similar cAMP production and β-arrestin 2 recruitment in
FSHR-transfected HEK293 cells (cAMP EC50 range = 12 ± 0.9–24 ± 1.7 ng/ml;
β-arrestin 2 EC50 range = 140 ± 14.1–313 ± 18.7 ng/ml; Kruskal-Wallis test; p ≥ 0.05;
n = 4). Kinetics analysis revealed that intracellular Ca2+ increased upon cell treatment
by 4µg/ml Gonal-f®, while equal concentrations of biosimilars failed to induced a
response (Kruskal-Wallis test; p < 0.05; n = 3). All preparations induced both 8 and
24 h-progesterone and estradiol synthesis in hGLC, while no different EC50s were
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demonstrated (Kruskal-Wallis test; p > 0.05; n = 5). Apart from preparation-specific
intracellular Ca2+ increases achieved at supra-physiological hormone doses, all
compounds induced similar intracellular responses and steroidogenesis, reflecting similar
bioactivity, and overall structural homogeneity.
Keywords: FSH, biosimilar, gonal-F, bemfola, ovaleap, glycosylation, assisted reproduction (ART)
INTRODUCTION
Follicle-stimulating hormone (FSH) is a heterodimeric
glycoprotein hormone produced by the pituitary and acting on
the gonads (1). In fertile women, FSH controls reproduction
supporting ovarian granulosa cell proliferation and follicular
growth by binding to its G protein-coupled receptor (FSHR) (2).
FSH shares a 92-amino acid residue α subunit with other
glycoprotein hormones and has a 111-amino acid residue,
hormone-specific β subunit (3). Two N-linked heterogeneous
oligosaccharide populations are bound to each protein
backbone subunit and are involved in hormone folding
and half-life, receptor binding, and activation (4, 5). After
gonadotropin binding, FSHR conformation rearrangements
occur, triggering intracellular signal transduction. Gαs protein
signaling leads to adenylyl cyclase stimulation and cyclic-AMP
(cAMP)/protein kinase A (PKA)-pathway activation (6, 7),
resulting in cAMP-response element binding protein (CREB)
(8, 9) and extracellular-regulated kinase 1/2 (ERK1/2) (10)
phosphorylation. These phospho-proteins are key players
modulating steroidogenesis, proliferation and survival/apoptosis
(8, 11), all molecular events underlying reproductive functions
(12). Upon ligand binding, FSHR recruits other heterotrimeric
Gα proteins, including Gαq and Gαi (13–16), as well as other
interactors (17), linking FSH action to multiple intracellular
signaling pathways, such as the rapidly-activated, phospholipase
C-dependent (18), cytosolic calcium cation (Ca2+) release
(19). FSHR internalization and recycling is mediated by β-
arrestin 1 and 2, which triggers G protein-independent ERK1/2
signaling (20, 21).
FSH exists in a number of isoforms differing in content
and composition of oligosaccharides attached to the protein
backbone (22). FSH glycoforms were proposed as biased
receptor ligands (5, 23, 24) due to isoform-specific contact
with FSHR (25) and intracellular signaling (26). Glycosylation
is a post-translational process influencing the isoelectric point
(pI) and half-life of the gonadotropin (27). In women, more
glycosylated and acidic FSH isoforms, mainly due to sialylation,
exhibit a prolonged in vivo half-life due to reduced kidney
clearance and are secreted mostly during the early and mid-
follicular phase, compared to FSH basic glycoforms, which
are predominant before ovulation (28, 29). Highly acidic
FSH isoforms are produced more after the menopause than
during the fertile lifespan (30), suggesting that glycoform
composition of circulating hormones is dynamic and might have
a physiological role.
Several formulations of exogenous FSH may be used in
assisted reproductive technologies (ART) to induce multiple
follicle development. Both urinary and recombinant FSH and
other gonadotropin preparations are commercially available, as
well as follitropin alfa biosimilar drugs, which are recombinant
compounds similar to the originator (31–33). Previous studies
attempted to address effects of these preparations on ART
outcomes, given their different glycosylation states featured as
post-translational modifications by the cellular source and/or
purification processes (31, 34, 35). In fact, previous analyses by
mass spectrometry found preparation-specific pattern of glycans
bound to the FSH β-subunits (36, 37).
In this study, the biochemical composition and hormone-
induced cell response of the originator follitropin alfa and two
biosimilar preparations were analyzed in vitro. Glycosylation
pattern was assessed in regard to cAMP production, Ca2+ release,
β-arrestin 2 recruitment, CREB, and ERK1/2 phosphorylation
and steroid (i.e., progesterone and estradiol) synthesis, which
were analyzed in human primary granulosa-lutein cells (hGLC)
and HEK293 cells transiently transfected with the human
FSHR cDNA.
MATERIALS AND METHODS
Follitropin Alfa Reference Preparation
(Gonal-f®) and Biosimilars
The reference follitropin alfa and two biosimilar preparations
were analyzed: Gonal-f R© provided by Merck KGaA (Darmstadt,
Germany), Ovaleap R© purchased from Teva Pharmaceutical
Industries (Tel Aviv, Israel) and Bemfola R© from Finox
Biotech (Kirchberg, Switzerland). Different batches of each
preparation were tested by performing both biochemical and
functional evaluations, as follows: two batches of Gonal-f R©
(AU016646, BA045956), two batches of Ovaleap R© (S27266,
R38915), and three batches of Bemfola R© (PPS30400, PNS30388,
PNS30230). Additional Gonal-f R© (199F005, 199F049, 199F051)
and Ovaleap R© (S06622) batches were used for glycopeptide
mapping. Comparison of hormone induced-signaling in vitro
were performed by stimulating cells with gonadotropins
concentrations expressed by mass rather than International
Units (IU), since the latter depends of the in vivo activity in rats
(38). Gonal-f R© and biosimilar dosages were determined starting
by the batch concentration declared by providers, consisting of
44µg/ml for Gonal-f R©, Ovaleap R© and Bemfola R©. Recombinant
human choriogonadotropin (hCG; Ovitrelle R©, Merck KGaA)
was used as a negative control where indicated.
Silver Staining and Western Blotting
Analysis
According to gonadotropin quantification provided by
the producers, 300 ng of each compound were subjected
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to 12% SDS-PAGE. Gel electrophoresis was performed
under denaturing-reducing or non-denaturing-non reducing
conditions, followed by silver staining and Western blotting.
Denaturing conditions consisted of boiling samples 5min at
100◦C, while reducing conditions were obtained by adding
2-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA),
disrupting disulfide bonds (39). Silver staining was performed
after acrylamide gel electrophoresis, as previously described
(40, 41). Briefly, fixation was performed by incubating gels 1 h
in 50% ethanol buffer, in the presence of 12% acetic acid and
5 × 10–4% formalin (all from Sigma-Aldrich). After washes,
gels were stained with 0.2% AgNO3 buffer 30 min-treatment
and signals were developed by 3% Na2CO3 buffer, 0.0005%
formalin and 4 × 10–4% Na2S2O3 before to be stopped.
Originator follitropin alpha and biosimilars were evaluated
by Western blotting using a rabbit anti-human polyclonal
primary antibody against FSHβ/FSH (SAB1304978; Sigma-
Aldrich), while the secondary antibody was anti-rabbit human
horseradish peroxidase (HRP)-conjugated (#NA9340V; GE
HealthCare, Little Chalfont, UK). Recombinant hCG (Ovitrelle;
Merck KGaA) was used as a negative control. Signals were
developed with ECL (GE HealthCare) and acquired using the
VersaDoc Imaging System (Bio-Rad Laboratories Inc., Hercules,
CA, USA).
Lectin ELISA Assay and Glycopeptide
Mapping
The technique was described previously (41, 42) and adapted
to preparations used in this study. A 96-well-microtiter plate
was coated overnight at 4◦C with the anti-human gonadotropin
α subunit monoclonal antibody HT13.3 (43), which recognizes
all human glycoprotein hormone α subunits, in 0.1M sodium
carbonate/hydrogen carbonate buffer (pH = 9.6). Plates were
washed with a saline buffer (TBS-T; 25mM Tris, 140mM NaCl,
3mM KCl, 0.05%, Tween 20; pH = 7.4) and non-specific
sites were saturated by 1 h-treatment at room temperature
(RT) using TBS-T containing 2% polyvinylpyrrolidone K30
(Fluka, Sigma-Aldrich). Duplicate 5 ng samples of each hormone
preparation were then incubated over-night, in 100 µl/well
of the saturation buffer. After washing, biotinylated lectins
(Vector laboratories Ltd, AbCys Biologie, Paris, France) were
placed into wells and incubated for 2 h at RT. Lectins used
were: Sambucus nigra agglutinin (SNA), Maackia amurensis
agglutinin (MAA), Artocarpus Polyphemus lectin (jacalin),
Ricinus communis agglutinin (RCA-1, ricin), Datura stramonium
agglutinin (DSA), wheat germ agglutinin (WGA), Phaseolus
vulgaris agglutinin (PHA-E) (Supplemental Table 1). They were
diluted in saturation buffer containing 1mM CaCl2, 1mM
MgCl2, and 1mM MnCl2. Plates were washed and peroxidase
labeled NeutrAvidinTM (Pierce, Interchim, Montluçon, France)
was added in each well (100 µl in TBS-T), for 1 h at
RT. After incubation with TMB ELISA peroxidase substrate
standard solution (UP664781; Interchim, Montluçon, France)
20min at RT, reactions were stopped by adding 50 µl/well of
2N H2SO4, and absorbance measured at 450 nm wavelength
using a spectrophotometer. Blank values, consisting of samples
maintained in the absence of hormones, were subtracted to
obtain ELISA data.
Additional information about reagents, glycopeptide
mapping, hydrophilic interaction chromatography, and mass
spectrometry analysis is provided in the supplemental section
(Supplemental Material and Methods).
Cell Culture and Transfection
HEK293 cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% FBS, 4.5 g/l glucose,
100 IU/ml penicillin, 0.1 mg/ml streptomycin, and 1mM
glutamine (all from Sigma-Aldrich). Transient transfections
were performed in 96-well plates using Metafectene PRO
(Biontex Laboratories GmbH, München, Germany), in order to
obtain exogenous FSHR and cAMP CAMYEL-, β-arrestin 2-
or aequorin Ca2+-BRET biosensor protein expression (15), as
previously described (41). For cAMP evaluation, 50 ng/well of
FSHR-expressing plasmid were mixed together with 0.5 µl/well
of Metafectene PRO in serum-free medium and incubated
20min. A 50 µl aliquot of cAMP CAMYEL biosensor-
expressing plasmid-Metafectene PRO mix was added to each
well-containing 1 × 105 cells, in a total volume of 200 µl/well,
and incubated 2-days before stimulation with gonadotropins.
One hundred ng/well of FSHR-Rluc8- and 100 ng/well of β-
arrestin 2 biosensor-expressing plasmids were used for evaluating
β-arrestin 2 recruitment. One hundred ng/well of FSHR- and
100 ng/well of aequorin biosensor-expressing plasmids were used
to prepare cells for measure changes in intracellular Ca2+. All
samples were prepared in duplicate and BRET measurements
were performed using 2-day transfected cells, in 40 µl/well PBS
and 1 mMHepes.
Human primary granulosa lutein cells (hGLC) were isolated
from ovarian follicles of about twenty donor women undergoing
oocyte retrieval for ART, following written consent and with
local Ethics Committee permission (Nr. 796 19th June 2014,
Reggio Emilia, Italy). Patients had to match these criteria:
absence of endocrine abnormalities and viral/bacterial infections,
age between 25 and 45 years. Cells were recovered from the
follicular washing fluid using a 50% Percoll density gradient
(GE Healthcare, Little Chalfont, UK), following a protocol
previously described (7, 44, 45). In order to restore expression
of gonadotropin receptors (46), hGLC were cultured 6 days,
then serum-starved over-night before use in experiments.
Cells were cultured at 37◦C and 5% CO2 in McCoy’s 5A
medium, supplemented with 10% FBS, 2mM L-glutamine,
100 IU/ml penicillin, 100µg/ml streptomycin and 250 ng/ml
Fungizone (Sigma-Aldrich).
BRET Measurement of cAMP Production,
and β-arrestin Recruitment and
Intracellular Ca2+ Increase
Intracellular cAMP and Ca2+ increase, and β-arrestin 2
recruitment were evaluated following a previously described
procedure (15, 41, 47). Cyclic-AMP production and Ca2+
increase were evaluated in transiently transfected HEK293 cells
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using the FSHR-expressing plasmid, together with the BRET-
based cAMP biosensor CAMYEL (48), or the aequorin Ca2+-
biosensor expression vector (49), respectively, while BRET
experiments cannot be performed in hGLC due to sub-optimal
transfection efficiency and the high mortality rate in this cell
model. Recruitment of β-arrestin 2 was assessed after transient
transfection of HEK293 cells with the C-terminal, Rluc-tagged
FSHR cDNA plasmid (provided by Dr. Aylin C. Hanyaloglu,
Imperial College, London, UK) and N-terminal, yPET-tagged
β-arrestin 2 (provided by Dr. Mark G. Scott, Cochin Institute,
Paris, France). Cells were incubated 30min in 40 µl/well
PBS and 1mM Hepes, in the presence or in the absence of
increasing concentrations of Gonal-f R© or biosimilars (1× 10−3-
1 × 103 ng/ml range), and intracellular cAMP increase and
β-arrestin 2 recruitment were measured upon addition of 10
µl/well of 5µM Coelenterzine h (Interchim). A 4 × 103 ng/ml
hormone concentration-induced intracellular Ca2+ increase was
evaluated over 100 s in transfected cells. Recombinant follitropin
alfa or biosimilar addition occurred at the 25 s time-point.
Light emissions were detected at 475 ± 30 and 530 ± 30 nm
wavelengths using the CLARIOstar plate reader equipped with
a monocromator (BMG Labtech, Ortenberg, Germany).
Evaluation of ERK1/2 and CREB
Phosphorylation
Hormone-induced ERK1/2 and CREB phosphorylation was
analyzed by Western blotting following a protocol previously
described (50). Human GLCs were seeded in 24-well plates
(1 × 105 cells/well) and treated for 15min with increasing
concentrations of gonadotropin (1 × 101-1 × 103 ng/ml range).
Cells were immediately lysed for protein extraction in ice-
cold RIPA buffer along with PhosStop phosphatase inhibitor
and a protease inhibitor cocktail (Roche, Basel, Switzerland).
Cell lysates were subjected to 12% SDS-PAGE and Western
blotting, while pERK1/2 and pCREB activation were evaluated
using specific rabbit antibodies (#9101 and #9198, respectively;
Cell Signaling Technology Inc., Danvers, MA, USA). Sample
loads were normalized to total ERK1/2 (#4695; Cell Signaling
Technology Inc.). Membranes were treated with secondary anti-
rabbit HRP-conjugated antibody (#NA9340V; GE HealthCare)
and signals developed with ECL (GE HealthCare). Signal
detection employed the VersaDoc system using the QuantityOne
analysis software (Bio-Rad Laboratories Inc.). Protein density
volumes were semi-quantitatively evaluated by the ImageJ
software (U. S. National Institutes of Health, Bethesda, MD,
USA) (51).
Gene Expression Analysis
Hormone 50% effective concentrations (EC50s) were calculated
from the cAMP dose-response curves and used for hGLC
treatments before FSH-target gene expression analysis. Cells
were seeded at 5 × 104 cells/well in 24-well plates and
exposed to gonadotropins for 8 h, and RNA was then
extracted using the automated workstation EZ1 Advanced XL
(Qiagen, Hilden, Germany). Equal amounts of total RNA
were retrotranscribed by iScript reverse transcriptase (Bio-Rad
Laboratories Inc.), according to a previously validated protocol
(52). The expression of STARD1 and CYP19A1 genes encoding
steroid-acute regulatory protein (StAR) and aromatase enzymes,
respectively, was evaluated by real time PCR (7, 44) using
specific primer sequences and protocols previously validated
(7). Target gene expression was normalized to ribosomal protein
subunit 7 (RPS7) gene expression using the 2−11Ct method (53).
Experiments were recorded as the mean value of duplicates.
Steroid Hormone Stimulation Protocol and
Measurement
Human GLCs were seeded in 24-well plates (4 × 104 cells/well)
and treated 8 or 24 h with increasing hormone concentrations (1
× 10−3-1× 103 ng/ml). Where appropriate, 1µM 4-androstene-
3,17-dione (androstenedione; #A9630; Sigma-Aldrich) was
added, as a substrate to be converted to estrogen by the aromatase
enzyme. Stimulations were terminated by freezing samples and
total progesterone or estradiol was measured in the cell media
by an immunoassay analyzer (ARCHITECT second Generation
system; Abbot Diagnostics, Chicago, IL, USA).
Statistical Analysis
Data were graphically represented using box and whiskers plots,
histograms, X-Y graphs and tables, and indicated as means ±
standard error of means (SEM). Western blotting results were
normalized to total ERK signals. Intracellular Ca2+ increase was
represented as kinetics of acceptor emissions measured at 525 ±
30 nm, and area under the curve (AUC) values were extrapolated
for comparisons between preparations. Dose-response curves
for cAMP and β-arrestin 2 were obtained by data interpolation
using non-linear regression. BRET data were represented as
induced BRET changes by subtracting the ratio of donor/acceptor
biosensor emissions of the untreated cells from the values
of the stimulated cells. Data distributions were analyzed by
D’Agostino and Pearson normality test, while differences were
evaluated by Kruskal-Wallis or Friedman test with Dunn’s
multiple comparison post-test and considered significant when
p < 0.05. Statistics were performed using the GraphPad
Prism 6.01 software (GraphPad Software Inc., San Diego,
CA, USA).
RESULTS
Western Blotting and Silver Staining
Analysis
Samples comprising 300 ng/well of non-denatured and denatured
Gonal-f R© and biosimilar preparations were loaded onto a 12%
acrylamide gel and separated by SDS gel electrophoresis
under denaturing-reducing and non-denaturing-non reducing
conditions. Denaturing conditions refer to 100◦C-boiled
samples, while reducing conditions were obtained by adding
2-mercaptoethanol. While no signals were detected under
non denaturing-non reducing conditions by Western blotting
(data not shown), two bands corresponding to the reference
follitropin alfa and biosimilar preparations were revealed under
denaturing-reducing conditions (Figure 1A). Ovaleap R© and
Gonal-f R© preparations featured an ∼20 KDa band, while a band
corresponding to about 23 KDa molecular weight characterized
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FIGURE 1 | Western blotting (A) and silver staining analysis (B,C) of Gonal-f® and biosimilars under non-denaturing-non reducing and denaturing-reducing
conditions. Samples comprising 300 ng of each preparation, according to the quantification provided by the manufacturer, were loaded. FSH presence was detected
by rabbit anti-human polyclonal primary antibody against FSHβ/FSH. Recombinant hCG was used as negative control. Samples were loaded as follows: (1) Ovaleap®
batch R38915, (2) Ovaleap® batch S27266, (3) Bemfola® batch PPS30400, (4) Bemfola® batch PNS30388, (5) Bemfola® batch PNS30230, (6) Gonal-f® batch
AU016646, (7) Gonal-f® batch BA045956, (8) recombinant hCG. (A) Evaluation of FSH preparations under denaturing-reducing conditions, by Western blotting, using
anti-FSHβ antibody. (B) Silver staining analysis of FSH preparations under non-denaturing-non reducing conditions. (C) Analysis of FSH preparations under
denaturing-reducing conditions, by silver staining.
Bemfola R©. All preparations displayed a 15 KDa band of varying
intensity. Recombinant hCG served as a negative control,
providing no signal using the anti-FSH antibody.
Analysis by silver staining under non denaturing-non
reducing conditions revealed that all preparations shared an
overall similar protein pattern characterized by a single band at
about 37 KDa molecular weight (Figure 1B). hCG resulted in
a 40 KDa band. All samples displayed signals at about 20 KDa
molecular weight (Figure 1C). Interestingly, no 15-KDa signals
were detected, oppositely to that demonstrated by Western
blotting, likely to be attributed to the low amount of FSHβ bound
by the antibody and undetectable using silver staining due to sub-
optimal sensitivity of this method (54). Three 35–20 KDa bands
corresponding to recombinant hCG Ovitrelle R© were detected, as
previously described (41).
Reference Follitropin Alfa and Biosimilar
Reactivity to Lectins
The carbohydrate structure of follitropin alfa and biosimilars
was investigated by ELISA, using a panel consisting of seven
lectins characterized by specific recognition of different glycan
features (Supplemental Table 1). Batches of each hormone were
considered as experimental replicates and absorbance values
measured at 450 nm were compared (Table 1).
Bemfola R© displayed structural peculiarities and variability,
emerging by lectin analysis (Supplemental Table 2), due
to significantly higher reactivity against ricin than other
preparations (Kruskal-Wallis test; p < 0.05; n = 16; Table 1).
Moreover, lectin assay revealed higher affinity of Bemfola R©
to DSA than Gonal-f R© (Kruskal Wallis test; p < 0.05; n = 6).
Ricin recognizes Galβ(1,4)GlcNAc monomers with higher
affinity in the absence of sialylation in the terminal galactose,
while DSA lectin binds Galβ(1,4) linked N-acetylglucosamine
oligomers and a branched pentasaccharide sequence, including
two N-acetyl lactosamine repeats linked to a mannose (55). No
signal was detected with SNA lectin regardless of the hormone
tested, indicating that sialic acid of the α(2,6) type is absent (56),
likely due to the absence of galactoside α(2,6) sialyltransferase
enzyme expression by CHO-K1 cells (57). Sialic acid of α(2,3)
type is detected by MAA lectin in all samples (58), without
any significant preparation-specific pattern. Jacalin failed to
produce any signal, demonstrating the absence of O-glycans of
the Galβ1-3GalNac or GalNac type (59). PHA-E lectin recognizes
bi-antennary complex-type N-glycan with outer Gal and
bisecting GlcNAc sequences (60), while WGA lectin reacts with
GlcNAc sequences and sialic acid (61). Antennarity (Table 2),
sialylation (Table 3), and sialic acid (Table 4) distribution
were analyzed by glycopeptide mapping of Gonal-f R© and
Ovaleap R© batches.
These features were similarly represented among preparations
(Kruskal-Wallis test; p ≥ 0.05; n = 6), as well as among batches
(Supplemental Results), at least in Gonal-f R© and Bemfola R©
(Chi-square test; p ≥ 0.05), which appeared to be homogeneous,
overall (Supplemental Tables 3–5).
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TABLE 1 | ELISA lectin analysis of reference and biosimilar follitropin alfa preparations.
Lectins Gonal–f® Ovaleap® Bemfola® pa
Absorbance (nm; means ± SEM*103) Absorbance (nm; means ± SEM*103) Absorbance (nm; means ± SEM*103)
MAA 74 ± 10 56 ± 1 60 ± 6 0.236
SNA −2 ± 1 −35 ± 1 −40 ± 1 0.236
Jacalin −1 ± 8 −9 ± 4 −17 ± 2 0.749
Ricin 120 ± 3 70 ± 2 180 ± 2 <0.0001
DSA 250 ± 8 370 ± 13 460 ± 8 0.001
PHA–E 1300 ± 30 1350 ± 40 1300 ± 30 0.814
WGA 100 ± 7 50 ± 5 80 ± 3 0.809
aKruskal Wallis test and Dunn’s post-test.
TABLE 2 | Antennarity of reference and biosimilar follitropin alfa preparations.
Glycosylation
site
Antennarity
distribution
Gonal-f®
(means ± SEM)
Ovaleap®
(means ± SEM)
pa
Asn52 Di-antennary 88.5 ± 0.5 90.6 ± 0.9 >0.999
Tri-antennary 11.0 ± 0.6 9.1 ± 0.7
Tetra-antennary 0.4 ± 0.1 0.5 ± 0.2
A-Index 2.1 ± 0.0 2.1 ± 0.0
Asn78 Di-antennary 91.5 ± 0.4 93.0 ± 0.5 >0.999
Tri-antennary 8.3 ± 0.4 6.9 ± 0.2
Tetra-antennary 0.2 ± 0.1 0.2 ± 0.1
A-Index 2.1 ± 0.0 2.1 ± 0.0
Asn7 Di-antennary 10.7 ± 0.4 6.0 ± 0.6 >0.999
Tri-antennary 66.5 ± 1.1 73.2 ± 1.7
Tetra-antennary 19.3 ± 0.9 17.3 ± 1.7
One Repeat
containing
3.3 ± 0.4 3.4 ± 0.5
A-Index 3.2 ± 0.0 3.2 ± 0.0
Asn24 Mono-antennary 0.4 ± 0.1 0.3 ± 0.0 >0.999
Di-antennary 87.5 ± 0.7 83.0 ± 1.2
Tri-antennary 7.7 ± 0.4 10.5 ± 0.3
Tetra-antennary 4.5 ± 0.3 6.1 ± 1.2
One Repeat
containing
0.1 ± 0.0 0.3 ± 0.0
A-Index 2.2 ± 0.0 2.2 ± 0.0
aKolmogorov-Smirnov test.
Evaluation of Intracellular cAMP Increase
and β-Arrestin 2 Recruitment
Transfected, FSHR-expressing HEK293 cells were used to
compare intracellular cAMP increases and β-arrestin 2
recruitment induced by 30-min treatment with increasing
doses of reference follitropin alfa and biosimilars. Different
batches of each preparation were tested and dose-response
curves obtained by plotting cAMP and β-arrestin 2 levels in
a semi-log X-Y graph (Supplemental Figure 1), in order to
calculate and compare EC50 values obtained from the individual
dose-response-curves (Figure 2).
Although preparation-specific carbohydrate structures
were detected (Table 1), no significant differences were found
TABLE 3 | Sialylation distribution in reference and biosimilar follitropin
alfa preparations.
Glycosylation
site
Sialylation
indexes
Gonal-f®
(means ± SEM)
Ovaleap®
(means ± SEM)
pa
Asn52 S-extent (%) 96.0 ± 0.1 97.5 ± 0.2 >0.999
S-index 2.0 ± 0.0 2.0 ± 0.0
Asn78 S-extent (%) 85.0 ± 0.3 90.1 ± 0.2 0.400
S-index 1.8 ± 0.0 1.9 ± 0.0
Asn7 S-extent (%) 91.3 ± 0.2 95.4 ± 0.4 0.100
S-index 2.9 ± 0.0 3.0 ± 0.0
Asn24 S-extent (%) 88.0 ± 0.2 92.3 ± 0.7 0.100
S-index 1.9 ± 0.0 2.0 ± 0.0
aMann-Whitney’s U-test.
TABLE 4 | Sialic acid distribution in reference and biosimilar follitropin alfa
preparations.
Glycosylation
site
Sialic acid Gonal-f®
(means ± SEM)
Ovaleap®
(means ± SEM)
pa
Asn52 NANA 97.3 ± 0.1 94.0 ± 0.1 >0.999
NGNA 0.2 ± 0.1 4.2 ± 0.3
O-Acetylated
NANA
2.5 ± 0.1 1.8 ± 0.3
Asn78 NANA 95.0 ± 0.3 89.9 ± 0.2 >0.999
NGNA 0.0 ± 0.0 4.4 ± 0.2
O-Acetylated
NANA
5.0 ± 0.3 5.8 ± 0.4
Asn7 NANA 97.5 ± 0.4 95.4 ± 0.5 >0.999
NGNA 0.0 ± 0.0 2.9 ± 0.2
O-Acetylated
NANA
2.5 ± 0.4 1.7 ± 0.6
Asn24 NANA 92.8 ± 0.3 90.2 ± 0.5 >0.999
NGNA 0.2 ± 0.1 3.6 ± 0.1
O-Acetylated
NANA
7.0 ± 0.4 6.2 ± 0.4
aKolmogorov-Smirnov test.
between Gonal-f R© and biosimilars’ EC50 required for activating
cAMP (Table 5; 12.9 ± 2.5–24.2 ± 6.0 ng/ml range; Kruskal-
Wallis test, p ≥ 0.05; n = 4; Figure 2A) and β-arrestin 2
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FIGURE 2 | EC50 of cAMP response and β-arrestin 2 recruitment induced by
Gonal-f® and biosimilars in transfected HEK293 cells. (A) Cells were
transiently co-transfected with FSHR and CAMYEL sensor. cAMP was
measured by BRET after 30min stimulation with increasing doses of Gonal-f®,
Ovaleap®, and Bemfola®. (B) Cells were transiently co-transfected with
FSHR-Rluc8 and β-arrestin 2 –YPET sensors. β-arrestin 2 recruitment was
measured by BRET after 30min stimulation with increasing doses of
hormones. EC50 values were extrapolated by non-linear regression. Data are
represented as box and whiskers graphs (Kruskal Wallis test, p ≥ 0.05; n = 4).
(Table 5; 140.7 ± 42.6–278.6 ± 56.9 ng/ml range; Kruskal-
Wallis test, p ≥ 0.05; n = 4; Figure 2B), consistent between
batches (cAMP: 10 ± 0.0–28 ± 0.0 ng/ml range; β-arrestin
2: 64 ± 0.0–610 ± 0.2 ng/ml range; Kruskal-Wallis test, p ≥
0.05; n = 4; Supplemental Figure 1) and confirming similar
potencies in vitro.
Analysis of pERK1/2 and pCREB Activation
The phosphorylation of ERK1/2 and CREB was evaluated in
hGLC, which naturally express endogenous FSHR. Cells were
treated for 15min with increasing hormone concentrations, and
phospho-protein activation was evaluated by Western blotting
and semi-quantitatively measured (Figure 3). Total ERK served
as a normalizer.
Similar ERK1/2 and CREB phosphorylation patterns were
observed after stimulating cells with increasing doses of different
batches of each preparation (Supplemental Figure 2). Mean
results from batches of Gonal-f R©, Ovaleap R©, and Bemfola R© were
calculated and average hormone-specific pERK1/2 and pCREB
activation results were reported (Figure 3). All preparations
induced protein phosphorylation within the 1.5–15 ng/ml range
(Kruskal-Wallis test, p < 0.05; n = 4), consistently between
different batches of each preparation (Friedman test, p ≥ 0.05;
n = 4). While no statistically significant differences between
TABLE 5 | Efficiency (EC50) of 30 min-cAMP and β-arrestin 2 production induced
by reference and biosimilar follitropin alfa preparations in transfected,
FSHR-expressing HEK293 cells.
Preparation EC50 cAMP
(ng/ml; means ± SEM;
n = 4)
pa EC50 β-arrestin 2
(ng/ml; means ± SEM;
n = 4)
pa
Gonal-f® 12.9 ± 2.5 0.561 278.6 ± 56.9 0.223
Ovaleap® 14.7 ± 3.9 140.7 ± 42.6
Bemfola® 24.2 ± 6.0 234.9 ± 57.2
aKruskal-Wallis test.
Gonal-f R© and biosimilars’ patterns of ERK1/2 phosphorylation
were detected, pCREB activation occurred upon cell treatment
by 0.5 ng/ml Gonal-f, differently to that obtained using both
biosimilars (Friedman test, p < 0.05; n = 4). Interestingly, cell
treatment by Gonal-f R© and Bemfola R© maximal concentrations
(15 ng/ml) resulted in slightly decreased levels of CREB
phosphorylation, not differing, however, significantly from the
plateau levels of pCREB activation.
STARD1 and CYP19A1 Gene Expression
Analysis
Expression of FSH target genes was analyzed by real time PCR
in hGLC. For this purpose, cells were stimulated 12 h by Gonal-
f R©, Ovaleap R© or Bemfola R©. Hormones were administered
at the EC50 calculated from cAMP data (12 ng/ml Gonal-f
R©
and Ovaleap R©, 24 ng/ml Bemfola R©). Total RNA was reverse-
transcribed to cDNA and used for STARD1 and CYP19A1 gene
expression analysis by real-time PCR. Data were normalized over
the RPS7 gene expression and represented as fold-increase over
unstimulated cells in a bar-graph as means± SEM (Figure 4).
Gonal-f R©, Ovaleap R©, and Bemfola R© resulted in about 15-
fold STARD1 and 3-fold CYP19A1 increase compared to the
basal level (Kruskal-Wallis test, p < 0.05; n = 4). In particular,
Ovaleap R©-induced CYP19A1 expression level lower than what
was obtained by Bemfola R© treatment (Kruskal-Wallis test,
p < 0.05; n = 4). Treatment using different batches did not
to affect STARD1 and CYP19A1 expression levels, since no
significant differences between lots of any preparation occurred
(Kruskal-Wallis test, p ≥ 0.05; n= 4; data not shown).
Steroid Synthesis Analysis
Progesterone production and androgen-to-estrogen conversion
were evaluated in hGLC treated for 8 or 24 h with hormones.
For this purpose, cells were maintained under continuous
stimulation by increasing gonadotropin concentrations (1 ×
10−3-1 × 103 ng/ml range) until reactions were stopped
by freezing cell plates. To evaluate estradiol synthesis,
androstenedione was added into wells as a substrate for the
aromatase enzyme. Eight- and Twenty-four hours progesterone
and estradiol dose-response curves were obtained and
evaluated by non-linear regression, EC50 values calculated,
and compared (Table 6).
Reflecting cAMP accumulation, cell stimulation with Gonal-
f R©, Ovaleap R©, and Bemfola R© resulted in similar 8- and 24-h
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FIGURE 3 | Evaluation of pERK1/2 and pCREB activation after Gonal-f® and biosimilars treatment of hGLC. Cells were stimulated by increasing doses of
preparations. ERK1/2 and CREB phosphorylation were evaluated after 15min by Western blotting (images representative of four independent experiments) (A).
(B,C) Densitometric analysis of pERK1/2 (B) and pCREB (C) signals. The values were normalized to total ERK and represented as means ± SEM, then statistically
evaluated (* = significant vs. control (0 dose); Kruskal Wallis test; p < 0.05; n = 4).
progesterone and estradiol production curves (Kruskal-Wallis
test; p≥ 0.05; n= 5), confirmed using different batches (Kruskal-
Wallis test; p ≥ 0.05; n= 5; data not shown), as well as in similar
progesterone and estradiol plateau levels (Kruskal-Wallis test;
p ≥ 0.05; n= 5; Supplemental Table 6).
Intracellular Ca2+ Increase
Kinetics of intracellular Ca2+ increase was evaluated in a
transiently transfected HEK293 cell line that co-expressed both
FSHR- and Ca2+-biosensors, by BRET. Cells were monitored for
over 100 s and 4 × 103 ng/ml hormone addition occurred at
the 25 s time-point (Figure 5). A 10–20-fold supra-physiological
FSH concentration was used, compared to FSH serum levels
described in cycling women (62), due to the lack of an
intracellular Ca2+ signal at lower hormone concentrations
(data not shown). Thapsigargin and vehicle treatment were
used as positive and negative controls, respectively. Data were
represented as means ± SEM. AUC values were calculated to
compare preparation-specific intracellular Ca2+ increase.
Addition of vehicle failed to induce any intracellular Ca2+
increase, confirming the lack of activity exerted by the solvent
used for hormone dilution on calcium response. After confirming
the absence of batch-specific results (Kruskal-Wallis test;
p ≥ 0.05; n = 3; data not shown), cell treatment by Gonal-f R©
induced rapid intracellular Ca2+ increase, which was about 230-
fold higher than vehicle (Kruskal-Wallis test; p< 0.05; n= 3) and
occurred within 1–2 s after hormone addition. Bemfola R© and
Ovaleap R© induced only a minimal, not significant intracellular
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FIGURE 4 | STARD1 and CYPA19A1 gene expression analysis. The
expression of STARD1 (A) and CYPA19A1 (B) gene was evaluated in hGLC
stimulated for 12 h with the EC50 of Gonal-f
® or biosimilars (12 ng/ml
Gonal-f® and Ovaleap®, 24 ng/ml Bemfola®) by real-time PCR. Each value
was normalized over the RPS7 gene expression (means ± SEM; n = 4).
Unstimulated cells served as control and are indicated as a dotted line.
(*= significant vs. Bemfola®, Kruskal Wallis test; p < 0.05).
TABLE 6 | FSH EC50 values (ng/ml) in inducing 8 h- and 24 h-progesterone and
estradiol production induced by reference and biosimilar follitropin alfa
preparations (means±SEM; n = 5) in human primary granulosa cells.
Preparation Progesterone pa Estradiol pa
8 h
Gonal-f® 1.5 ± 0.3 10.3 ± 4.4
Ovaleap® 10.9 ± 3.7 0.285 5.6 ± 1.9 0.899
Bemfola® 4.4 ± 1.5 7.1 ± 2.6
24 h
Gonal-f® 15.4 ± 5.5 3.3 ± 1.0
Ovaleap® 5.7 ± 1.2 0.799 2.5 ± 0.8 0.803
Bemfola® 7.3 ± 2.0 3.4 ± 1.0
aKruskal-Wallis test.
Ca2+ increase (Kruskal-Wallis test; p ≥ 0.05; n = 3). Maximal
levels of intracellular Ca2+ were achieved under thapsigargin
treatment, which served as a positive control and induced an
about 600-fold greater increase compared to the basal level
(Kruskal-Wallis test; p< 0.05; n= 3).
DISCUSSION
We compared the biochemical profiles and hormone-induced
cell responses of the reference follitropin alfa (Gonal-f R©) and
two biosimilars, Ovaleap R© and Bemfola R©, in vitro, revealing
FIGURE 5 | Calcium response kinetics in transfected HEK293 cells treated
with Gonal-f® or biosimilars. Cells were transiently co-transfected with FSHR
and aequorin sensors, then stimulated in duplicates with a fixed dose (4 × 103
ng/ml) of (A) Gonal-f®, (B) Ovaleap®, (C) Bemfola®. (D) Thapsigargin, PBS
and hormone diluent were used as positive and negative controls, respectively.
BRET signal was measured for 100 s. Data are represented as means ± SEM
(n = 3). Area under the curve (AUC) values were calculated and differences
were considered for p < 0.05 (Kruskal Wallis test).
overall comparable hormone-induced intracellular signaling and
steroidogenesis. Only the originator follitropin alfa induced
hormone-specific pattern of CREB phosphorylation and, at
supra-physiological concentrations (62), intracellular Ca2+
increase to transfected, FSHR-expressing cell lines.
Several gonadotropin formulations are commercially
available, differing by source, purification process, and purity.
Clinicians choose freely what preparation or combination of
preparations will be administered to women undergoing ART
(35). These preparations may differ in oligosaccharide content
and number of branches attached to the protein backbone (63),
depending on the glycosyltransferases equipment of the source
cell. Gonal-f R© is expressed by Chinese hamster ovary (CHO)
cell lines (64), ensuring high bioactivity and batch-to-batch
consistency (65, 66). Bemfola R© is produced by a pre-adapted
dihydrofolate reductase deficient CHO (CHO DHFR-) host cell
line (67) and has demonstrated similar efficacy and safety in vivo
as compared to the reference follitropin alfa, in a multi-center
phase 3 study (68). Ovaleap R© is also produced by a CHO-derived
cell line after adaptation to serum free conditions (69) and has
been demonstrated to be similar to follitropin alfa in vivo in a
phase 3 clinical study (70).
Gonal-f R© and Ovaleap R© share two similar Western blotting
patterns under denaturing and reducing conditions, likely due to
specifically glycosylated FSH β-subunits (36, 37), while Bemfola R©
featured a ∼23 instead of 20 KDa band according to its
specific glycosylation pattern detected by mass spectrometry
(36). Most of these signals were confirmed by silver staining,
except for the absence of the 15 KDa band, likely due to
sub-optimal sensitivity of the method (54). Analysis of native
proteins contained in Gonal-f R© and Ovaleap R© batches, which
were obtained by omitting treatment of samples by 100◦C-
heating and 2-mercaptoethanol reduction, revealed a single 37
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KDa band consistent with the FSH heterodimer (71), while
Bemfola R© resulted in slightly higher apparent molecular weight.
On the other hand, lectin assay revealed higher DSA signal in
Bemfola R© than Gonal-f R©, likely due to different multiantennary
complex structures on N-glycans demonstrated by glycopeptide
mapping (36), and suggesting Bemfola R©-specific glycosylation
patterns. Lower ricin binding to Ovaleap R© than to Bemfola R©
and Gonal-f R© indicated a different content of Galβ1-4GlcNAc
molecules (72).
Naturally occurring variations in carbohydrate structures
were characterized during the follicular phase of the cycle (22)
and might affect FSH bioactivity in vivo (73). Highly glycosylated
FSH isoforms prevail at the early stages, while serum levels
of less-acidic (sialylated) glycoforms increase at the mid-cycle
until ovulation (29), suggesting a functional role of glycosylation
and sialylated structures in modulating FSH bioactivity (26).
However, crystallographic structures of FSH in complex with
the receptor ectodomain suggested that carbohydrates are not
located in the binding interface between the hormone and
FSHR (74, 75), making unclear the physiological role of
FSH sugar residues in hormone activity. In fact, analysis of
signaling cascades revealed that cell treatment by Gonal-f R© and
biosimilars resulted in similar dose-response curves for both
cAMP and β-arrestin 2, as well as ERK1/2 phosphorylation
pattern. These results were replicated using different batches
and are strengthened by similar ratios between EC50s observed
for cAMP and β-arrestin 2 recruitment, confirming previously
reported results obtained with follitropin alfa (15). On the other
hand, the crystallographic structure of the human FSH bound
to the extracellular binding domain of FSHR was obtained
using partially deglycosylated hormone-receptor complexes (74).
Therefore, it might be not fully descriptive of the role of sugar
chains linked to the hormone in binding the receptor, providing
a basis for explaining preparation-specific features, such as the
higher potency of Gonal-f R© in inducing CREB activation. These
characteristics are likely linked to a relatively wide FSH EC50
range of progesterone response (Table 6; from 1.5± 0.3 to 10.9±
3.7 ng/ml), although not significantly different, presumably due
to biased signaling (76, 77) of preparations.
Preparation-specific glycosylation patterns may be reflected
by cellular response to supra-physiological doses of FSH in vitro.
Biosimilar compounds induce barely detectable Ca2+ increases in
FSHR-expressing HEK293 cells, which differed to that of Gonal-
f R© as previously reported using human pituitary FSH (78). FSHR
is known to modulate intracellular Ca2+ increase via a molecular
mechanism involving the phospholipase C (19). However,
Gonal-f R©-induced Ca2+ increase was obtained by hormone
concentrations usually not achieved in vivo (62), while cAMP
activation, and ERK1/2 CREB phosphorylation occurs at FSH
doses achievable in serum, suggesting a supraphysiological shift
from Gαs to Gαq protein-mediated activation of intracellular
signaling cascades (8, 79). These data should be confirmed in
other cell models, such as hGLC, since the pattern of intracellular
signaling pathways is cell-specific and depends on the number
and variety of GPCRs located at the cell surface (12, 79–81). Most
importantly, preparation-specific activation of cAMP/β-arrestin
2 and intracellular Ca2+ increase indicated that these hormones
might act as biased ligands under particular conditions, as well as
the high sensitivity of the cAMP response detectable in vitro.
Confirming similar, FSH-induced STARD1 expression in
hGLC, no differences in 8 and 24 h-progesterone and
estradiol production between hormones was found, despite their
structural peculiarities and lower Ovaleap R©-induced CYP19A1
expression levels. Previous studies reported preparation-specific
intracellular signaling resulting in similar long-term effects,
measurable as 24-h steroid production (41, 45). These data
are reminiscent of the earlier debate about recombinant and
urinary FSH preparations, which provided similar pregnancy rate
per fresh transfer (35, 68), as well as similar pharmacokinetic
profiles (82). However, the matter is still debated. Different ART
outcomes, depending on the use of Bemfola R© vs. Gonal-f R©,
were postulated, possibly explained by different glycosylation,
especially sialylation patterns between the two preparations
and/or higher batch-to-batch variability (36) and estradiol
production (82), observed with Bemfola R©. Further in vivo
investigations and extensive clinical experience are necessary to
characterize the possible occurrence of biosimilar preparation-
specific effects (31).
CONCLUSIONS
Different glycosylation profiles are characteristic of the follitropin
alfa and subsequent biosimilar preparations, likely due to the
specific enzymatic equipment of the source cell lines. These
molecular peculiarities do not result in major preparation-
specific signals mediated at the intracellular level and steroid
synthesis, which were found to be overall similar when follitropin
alfa and biosimilars are used at concentrations resembling those
obtained under physiological conditions. In light of the specific
molecular features of these commercial compounds and of
the slight differences demonstrated by the present study, and
considering the relevance of their use for clinical purposes,
the comparison between the reference follitropin alfa and
biosimilar preparations merits further investigations in a variety
of experimental settings.
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increasing doses of (A) Gonal-f®, (B) Ovaleap®, and (C) Bemfola® batches.
(D–F) Recruitment of β-arrestin 2 was measured in FSHR-Rluc8 and β-arrestin
2-YPET biosensor-expressing cells by BRET, after 30-min treatment of with
increasing doses of (D) Gonal-f®, (E) Ovaleap®, and (F) Bemfola®. Data were
represented as means ± SEM. No significant differences between EC50 values
were found (Kruskal Wallis test, p ≥ 0.05; n = 4).
Supplemental Figure 2 | Densitometric analysis of pERK1/2 and pCREB
activation induced by different batches of Gonal-f® and biosimilars in hGLC. Cells
were stimulated with increasing doses of FSH preparations and 15 min- ERK1/2
(A) and CREB (B) phosphorylation evaluated by semi-quantitative Western
blotting. Values were normalized to total ERK and represented as means ± SEM.
Differences between batches of each preparation was statistically evaluated
(Kruskal Wallis test; p ≥ 0.05; n = 4).
Supplemental Table 1 | Lectin specific binding sites.
Supplemental Table 2 | ELISA lectin analysis of different batches of originator
and biosimilar follitropin alfa. Lectins were used as follows: MAA (n = 20), SNA
(n = 14), Jacalin (n = 6), ricin (n = 16), DSA (n = 6), PHA-E (n = 8), WGA (n = 8).
Hormone reactivity to lectins was represented as absorbance measured at
450 nm (means ± SEM)∗103, after subtracting values obtained in the absence of
gonadotropin. Data were analyzed by Kruskal-Wallis test, taking p < 0.05
as significant.
Supplemental Table 3 | Antennarity distribution of Gonal-f® and
Ovaleap® batches.
Supplemental Table 4 | Sialylation distribution of follitropin alfa and Ovaleap®
batches. Asn7, Asn24, Asn52, and Asn78 were analyzed in terms of percentage.
Supplemental Table 5 | Sialic acids distribution of follitropin alfa originator and
Ovaleap® batches.
Supplemental Table 6 | Eight h- and twenty four hours-progesterone and
estradiol plateau levels induced by Gonal-f® and biosimilar stimulation of human
primary granulosa cells. Data are represented as means ± SEM (Kruskal-Wallis
test, p ≥ 0.05; n = 5).
Supplemental Data Sheet 1 | Glycopeptide mapping.
Supplemental Data Sheet 2 | Supplemental Results.
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